Search research articles
Contact Us
Filters
Showing results (251-260 of 305) with videos related to
Page
of 31
Sort By:
The New England Journal of Medicine
|
June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Clinical Lung Cancer
|
August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Targeted Oncology
|
March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Nature Medicine
|
March 18, 2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
Roy S Herbst, Thomas John, Christian Grohé, et al.
JCI Insight
|
June 18, 2024
A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Paul R Stabach, Dominique Sims, Eduardo Gomez-Bañuelos, et al.
The Lancet. Respiratory Medicine
|
October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Myung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.
Nature Cancer
|
February 5, 2022
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
Amy L Cummings, Jaklin Gukasyan, Henry Y Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Lancet (London, England)
|
October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
Page
of 31
Search research articles
Search
Showing results (251-260 of 305) with videos related to
Sort By:
Page
of 31
The New England Journal of Medicine
|
June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Clinical Lung Cancer
|
August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Targeted Oncology
|
March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Nature Medicine
|
March 18, 2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
Roy S Herbst, Thomas John, Christian Grohé, et al.
JCI Insight
|
June 18, 2024
A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Paul R Stabach, Dominique Sims, Eduardo Gomez-Bañuelos, et al.
The Lancet. Respiratory Medicine
|
October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Myung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.
Nature Cancer
|
February 5, 2022
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
Amy L Cummings, Jaklin Gukasyan, Henry Y Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Lancet (London, England)
|
October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
Page
of 31